Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria

Journal of the American Society of Nephrology

Volumn 25, Issue 12, 2014, Pages 2916-2925

  Skupien, Jan ^a,b   Warram, James H ^a   Smiles, Adam ^a   Galecki, Andrzej ^c,d   Stanton, Robert C ^a   Krolewski, Andrzej S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DEATH; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RISK REDUCTION; AGED; ANALYSIS; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; URINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEINURIA; TREATMENT OUTCOME;

EID: 84906695117     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013091002     Document Type: Article

References (26)

1. Rosolowsky ET, Skupien J, Smiles AM, Niewczas M, Roshan B, Stanton R, Eckfeldt JH, Warram JH, Krolewski AS: Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 22: 545-553, 2011
2. Forsblom C, Harjutsalo V, Thorn LM, Wadén J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH; FinnDiane Study Group: Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 22: 537-544, 2011
3. Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, Warram JH, Krolewski AS: Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 18: 1353-1361, 2007
4. Perkins BA, Ficociello LH, Roshan B, Warram JH, Krolewski AS: In patients with type1 diabetes and new-onsetmicroalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 77: 57-64, 2010
5. Skupien J, Warram JH, Smiles AM, Niewczas MA, Gohda T, Pezzolesi MG, Cantarovich D, Stanton R, Krolewski AS: The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int 82: 589-597, 2012
6. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159-2167, 2003
7. de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B; DCCT/EDIC Research Group: Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365: 2366-2376, 2011
8. Viberti GC, Mackintosh D, Bilous RW, Pickup JC, Keen H: Proteinuria in diabetes mellitus: Role of spontaneous and experimental variation of glycemia. Kidney Int 21: 714-720, 1982
9. Ciavarella A, Vannini P, Flammini M, Bacci L, Forlani G, Borgnino LC: Effect of long-termnear-normoglycemia on the progression of diabetic nephropathy. Diabete Metab 11: 3-8, 1985
10. van Ballegooie E, de Jong PE, Donker AJ, Sluiter WJ: The effect of continuous subcutaneous insulin infusion on renal function in type I diabetic patients with and without proteinuria. Proc Eur Dial Transplant Assoc Eur Ren Assoc 21: 722-724, 1985
11. Bending JJ, Viberti GC, Watkins PJ, Keen H: Intermittent clinical proteinuria and renal function in diabetes: Evolution and the effect of glycaemic control. Br Med J (Clin Res Ed) 292: 83-86, 1986
12. Alaveras AE, Thomas SM, Sagriotis A, Viberti GC: Promoters of progression of diabetic nephropathy: The relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant 12[Suppl 2]: 71-74, 1997
13. Mulec H, Blohmé G, Grände B, Björck S: The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant 13: 651-655, 1998
14. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH: Progression of diabetic nephropathy. Kidney Int 59: 702-709, 2001
15. Goel G, Perkins BA: Can improved glycemic control slow renal function decline at all stages of diabetic nephropathy? Semin Nephrol 32: 423-431, 2012
16. Fioretto P, Mauer SM, Bilous RW, Goetz FC, Sutherland DE, Steffes MW: Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patientswith their own kidneys. Lancet 342: 1193-1196, 1993
17. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75, 1998
18. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 332: 1251-1255, 1995
19. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993
20. Gu Z, Aimetti AA, Wang Q, Dang TT, Zhang Y, Veiseh O, Cheng H, Langer RS, Anderson DG: Injectable nano-network for glucose-mediated insulin delivery. ACS Nano 7: 4194-4201, 2013
21. Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, MacMahon S, Cooper ME, Hamet P, Marre M, Mogensen CE, Poulter N, Mancia G, Cass A, Patel A, Zoungas S; ADVANCE Collaborative Group: Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 83: 517-523, 2013
22. Ismail-Beigi F, Craven TE, O'Connor PJ, Karl D, Calles-Escandon J, Hramiak I, Genuth S, Cushman WC, Gerstein HC, Probstfield JL, Katz L, Schubart U; ACCORD Study Group: Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int 81: 586-594, 2012
23. Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 7: 930-937, 1996
24. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
25. Henderson R, Diggle P, Dobson A: Joint modelling of longitudinal measurements and event time data. Biostatistics 1: 465-480, 2000
26. Guo X, Carlin BP: Separate and joint modeling of longitudinal and event time data using standard computer packages. Am Stat 58: 16-24, 2004